Biotechnology
T-cells treated by Turn Biotechnologies show increased cancer-killing effectiveness
* Preclinical data showing how ERA™, eTurna™ technologies turbocharge T-cell therapies presented at New Frontiers of RNA Nanotherapeutics meeting today * ERA™ boosts CAR T-cell efficacy by overcoming T-cell exhaustion that inhibits cancer cures * eTurna™ delivery platform delivers more healt...
2022-10-24 23:30
2638
deCODE genetics publishes multiomics study of nonalcoholic fatty liver disease
Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets for nonalcoholic fatty liver disease (NAFLD). REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish t...
2022-10-24 23:00
2680
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 24, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment o...
2022-10-24 21:00
2515
Transcenta to Participate in Four Upcoming Conferences
SUZHOU, China, Oct. 24, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development, and manufacturing of antibody-based therapeutics, announces that the management ...
2022-10-24 21:00
3516
WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities
* WuXi Biologics adds further capacity and capability for drug product fill & finish, providing global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP HANGZHOU, China, Oct. 23, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading gl...
2022-10-24 08:30
1865
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults
GAITHERSBURG, Md., Oct. 22, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received eme...
2022-10-22 03:25
7095
Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
- XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan - Antengene plans to submit for national health insurance reimbursement inTaiwan for XPOVIO® in Q4 2022 SHANGHAI and HONG KONG, Oct. 21, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...
2022-10-21 20:37
4671
SIRONA completes enrollment - A leap in the DCB treatment of femoropopliteal arterial disease
TAMPA, Fla., Oct. 21, 2022 /PRNewswire/ -- Concept Medical Inc.
2022-10-21 20:36
3053
SK bioscience Appoints New Executives towards Global Business Growth
* Global experts continue to join SK bioscience, while its U.S. corporate entity is being established * Company plans to strategically invest in personnel, innovation & infrastructure to ensure global competitiveness SEOUL, South Korea, Oct. 21, 2022 /PRNewswire/ -- SK bioscience, a global in...
2022-10-21 20:00
2308
MGI Contributes to Thailand's Roadmap for Genomic Medicine in Genomics Thailand Initiative
BANGKOK, Oct, 21 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, today announced the supply of its products* to support the sequencing of the genomes of 50,000 Thai individuals as part of the Genomics Thailand Initiativ...
2022-10-21 11:00
2846
AUM Biosciences and Asymchem Complete Phase II API Production Campaign of Novel TRK Inhibitor
TEDA TIANJIN, P.R. China and SINGAPORE, Oct. 20, 2022 /PRNewswire/ -- Asymchem (stock code: 002821.SZ), a leading global contract development and manufacturing service provider, and AUM Biosciences (AUM), a global clinical stage biotech company, focused on discovering, acquiring and developing ne...
2022-10-20 20:30
2232
Official Ground-breaking Ceremony of Wuhan Synthetic Biology Innovation Center & CABIO R&D Center Investment Project
WUHAN, China, Oct. 20, 2022 /PRNewswire/ -- On October 19th, 2022, the investment project of the CABIO R&D Center officially commenced in Wuhan Optical Valley. Upon the basis of the said investment project, the ground-breaking ceremony of the "Wuhan Synthetic Biology Innovation Center" project, ...
2022-10-20 20:30
1831
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States
CAMBRIDGE, Mass., ROTTERDAM and SUZHOU, China, Oct. 20, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 inthe United States. This study will eva...
2022-10-20 16:20
1560
BGI Australia Receives NATA Certification for Clinical Whole Exome Sequencing
BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencing inAustralia, paving the way for the global life sciences company to provide clinical sequencing ...
2022-10-20 15:31
1726
BGI Australia Receives NATA Certification for Clinical Whole Exome Sequencing
BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencing inAustralia, paving the way for the global life sciences company to provide clinical sequencing ...
2022-10-20 15:27
1446
AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting
SUZHOU, China and ROCKVILLE, Md., Oct. 19, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it will release results from the Phase I fir...
2022-10-20 07:16
1230
Consumer Healthcare Products (CHP) Australia Streamlines Content Management for Life Sciences Companies with Veeva Vault PromoMats
CHP's AdCheck independent advertising advisory service creates content
management and communication efficiencies for members
SYDNEY, Oct. 20, 2022 /PRNewswire/ -- Veeva Systems
2022-10-20 07:05
2305
NCCN Guidelines for Patients Win Award for Excellence in Cancer Patient Education from CPEN
National Comprehensive Cancer Network's breast cancer patient resources honored for unique support of diversity, equity, and inclusion, available free at NCCN.org/patientresources. PLYMOUTH MEETING, Pa., Oct. 19, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance ...
2022-10-19 20:37
1183
SeekIn Presents New Data Supporting its Pan-cancer Early Detection Test at the Early Detection of Cancer Conference 2022
The large case-control study demonstrates that SeekInCare® has 68.0% sensitivity at 98.0% specificity in 27 different cancer types as a whole. In both retrospective and prospective studies, the solid performance of SeekInCare® puts it into best-in-class category of multi-cancer early detection (...
2022-10-19 20:30
1121
Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults
-- Levels of neutralizing antibodies generated by PTX-COVID19-B were non-inferior to Comirnaty®-- -- PTX-COVID19-B was well tolerated with no safety signals-- -- Everest is filing IND applications for phase 3 clinical trials for booster indication-- SHANGHAI, Oct. 19, 2022 /PRNewswire/ -- Everest...
2022-10-19 20:15
2013
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
6098
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4449
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4045
TCTM Filed 2023 Annual Report on Form 20-F
2024-04-20 05:48
3322
Dingdong Files Its Annual Report on Form 20-F
2024-04-20 05:00
3069